Alice T Shaw

Alice T Shaw

UNVERIFIED PROFILE

Are you Alice T Shaw?   Register this Author

Register author
Alice T Shaw

Alice T Shaw

Publications by authors named "Alice T Shaw"

Are you Alice T Shaw?   Register this Author

100Publications

4984Reads

40Profile Views

Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.

Clin Lung Cancer 2019 Sep 11;20(5):339-349. Epub 2019 May 11.

Department of Radiology, Massachusetts General Hospital, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.05.006DOI Listing
September 2019

Clinical Management of Adverse Events Associated with Lorlatinib.

Oncologist 2019 Aug 19;24(8):1103-1110. Epub 2019 Mar 19.

Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693708PMC
August 2019

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.

J Thorac Oncol 2019 May 18;14(5):835-843. Epub 2019 Jan 18.

Massachusetts General Hospital, Center for Integrated Diagnostics, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.032DOI Listing
May 2019

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.

J Thorac Oncol 2019 May 18;14(5):816-824. Epub 2019 Jan 18.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486857PMC
May 2019

BRAF Mutation Class and Clinical Outcomes-Response.

Clin Cancer Res 2019 May;25(10):3189

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0422DOI Listing
May 2019

Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.

J Thorac Oncol 2019 Apr 7;14(4):683-690. Epub 2018 Dec 7.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183351
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.12.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440803PMC
April 2019

Refining precision cancer therapy in ALK-positive NSCLC.

EBioMedicine 2019 Mar 6;41:9-10. Epub 2019 Feb 6.

Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.01.059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444055PMC
March 2019

Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.

Lung Cancer 2019 03 16;129:80-84. Epub 2019 Jan 16.

Department of Radiology, Massachusetts General Hospital, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002193002
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2019.01.007DOI Listing
March 2019

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Clin Cancer Res 2019 Jan 17;25(1):158-165. Epub 2018 Sep 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2062DOI Listing
January 2019

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.

J Thorac Oncol 2018 11;13(11):e226-e227

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183077
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.06.021DOI Listing
November 2018

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

J Clin Oncol 2018 09 16;36(26):2693-2701. Epub 2018 May 16.

D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Dae Ho Lee, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Corey J. Langer, University of Pennsylvania, Philadelphia, PA; Alice T. Shaw, Massachusetts General Hospital, Boston; William Reichmann, Jeff Haney, Tim Clackson, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; Rudolf M. Huber, University Hospital of Munich, Munich, Germany; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Lyudmila A. Bazhenova and Kathryn A. Gold, University of California San Diego Moores Cancer Center, La Jolla; Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Irvine, CA; Howard L. West, Swedish Cancer Institute, Seattle, WA; and Scott N. Gettinger, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.5841
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.5841DOI Listing
September 2018

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Lung Cancer 2018 08 22;122:67-71. Epub 2018 May 22.

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062851PMC
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.

Int J Radiat Oncol Biol Phys 2018 07 22;101(3):624-629. Epub 2018 Mar 22.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.02.175DOI Listing
July 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 04 31;13(4):550-558. Epub 2018 Jan 31.

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183003
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.01.012DOI Listing
April 2018

Tumour heterogeneity and resistance to cancer therapies.

Nat Rev Clin Oncol 2018 02 8;15(2):81-94. Epub 2017 Nov 8.

Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 7B, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.166DOI Listing
February 2018

ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?

Authors:
Alice T Shaw

Clin Adv Hematol Oncol 2017 Dec;15(12):941-945

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
December 2017

Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.

Am Soc Clin Oncol Educ Book 2017 ;37:619-629

From the Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hematology/Oncology Fellowship Program, Moffitt Cancer Center, Tampa, FL; University of South Florida, Tampa, FL; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175197DOI Listing
November 2017

Recent Advances in Targeting ROS1 in Lung Cancer.

J Thorac Oncol 2017 11 14;12(11):1611-1625. Epub 2017 Aug 14.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659942PMC
November 2017

Fast, Food and Ceritinib in ALK-Positive NSCLC.

J Thorac Oncol 2017 09;12(9):1341-1343

Department of Medicine, Massachusetts General Hospital, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.07.012DOI Listing
September 2017

Expanding the Roster of ROS1 Inhibitors.

J Clin Oncol 2017 08 18;35(23):2595-2597. Epub 2017 May 18.

Ibiayi Dagogo-Jack and Alice T. Shaw, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.2586DOI Listing
August 2017

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2017 08 6;377(9):829-838. Epub 2017 Jun 6.

From Lausanne University Hospital, Lausanne (S.P.), and F. Hoffmann-La Roche, Basel (A.Z., E.M., S. Golding, B.B., J.N.) - both in Switzerland; University of Colorado, Denver (D.R.C.); Massachusetts General Hospital, Boston (A.T.S.); University of Michigan, Ann Arbor (S. Gadgeel); Samsung Medical Center, Sungkyunkwan University School of Medicine (J.S.A.), and Seoul National University Hospital (D.-W.K.) - both in Seoul, South Korea; Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.); Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France (M.P.); Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland (R.D.); Catalan Institute of Oncology, Barcelona (R.R.); Roche Innovation Center, New York (P.N.M.); and State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1704795DOI Listing
August 2017

J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.

Lancet 2017 07 10;390(10089):3-4. Epub 2017 May 10.

Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)31074-7DOI Listing
July 2017

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 05 11;12(5):872-877. Epub 2017 Jan 11.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403618PMC
May 2017

Lung Cancer: A Wily Genetic Opponent.

Cell 2017 05;169(5):777-779

Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.05.001DOI Listing
May 2017

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

J Immunother 2017 04;40(3):108-113

*Massachusetts General Hospital Cancer Center †Department of Radiology, Massachusetts General Hospital, Harvard Medical School ‡Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000159DOI Listing
April 2017

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Cancer Discov 2017 02 25;7(2):137-155. Epub 2017 Jan 25.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296241PMC
February 2017

Raising the bar on first-line immunotherapy in lung cancer.

Lancet Oncol 2017 01 5;18(1):2-3. Epub 2016 Dec 5.

Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30594-0DOI Listing
January 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2016 11 17;11(11):2027-2032. Epub 2016 Aug 17.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.126DOI Listing
November 2016

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

J Thorac Oncol 2016 11 20;11(11):2022-2026. Epub 2016 Aug 20.

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864163084
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2016.06.032DOI Listing
November 2016

Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?

J Clin Oncol 2016 10 25;34(28):3363-5. Epub 2016 Jul 25.

Massachusetts General Hospital Cancer Center, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.5891DOI Listing
October 2016

Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics.

J Clin Oncol 2016 Oct;34(30):3605-3608

Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.8573DOI Listing
October 2016

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.

J Thorac Oncol 2016 09 11;11(9):1522-8. Epub 2016 Jun 11.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002360PMC
September 2016

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol 2016 08 22;11(8):1242-1245. Epub 2016 Jun 22.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.013DOI Listing
August 2016

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Oncologist 2016 08 27;21(8):964-73. Epub 2016 Jun 27.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978553PMC
August 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

Resisting Resistance: Targeted Therapies in Lung Cancer.

Trends Cancer 2016 07;2(7):350-364

Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, 32 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091655PMC
July 2016

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

Oncologist 2016 06 31;21(6):662-3. Epub 2016 May 31.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912373PMC
June 2016

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.

Clin Cancer Res 2016 06;22(11):2613-7

U.S. Food and Drug Administration, Silver Spring, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2643DOI Listing
June 2016

Crizotinib Resensitization by Compound Mutation.

N Engl J Med 2016 05;374(18):1790-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1601366DOI Listing
May 2016

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

JAMA Oncol 2016 Apr;2(4):541-3

Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.5009DOI Listing
April 2016

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1670-4

*Department of Medicine, Massachusetts General Hospital, Boston, MA; †Department of Pathology, Massachusetts General Hospital, Boston, MA; ‡Memorial Sloan Kettering Cancer Center, New York, NY; ‖Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; §Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; ¶Department of Medicine, Georgetown University Medical Center, Washington, DC; #University of California Irving Health, Orange, CA; **Dana-Farber Cancer Institute, Boston, MA; ††Beth Israel Deaconess Medical Center, Boston, MA; and ‡‡Ignyta, Inc., San Diego, CA.

View Article

Download full-text PDF

Source
http://ignyta.com/wp-content/uploads/2016/01/Durable-Clinica
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S155608641535087
Publisher Site
http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748PMC
December 2015

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

J Clin Oncol 2015 Jun 26;33(17):1881-8. Epub 2015 Jan 26.

Daniel B. Costa, Beth Israel Deaconess Medical Center, Harvard Medical School; Alice T. Shaw, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Sai-Hong I. Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine; S. Martin Shreeve, Paulina Selaru, and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center; Patrick Schnell, Pfizer Oncology, New York, NY; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China; Anna Polli, Pfizer Oncology, Milan; Lucio Crinò, Perugia University Medical School, Perugia, Italy; Robin Wiltshire, Pfizer Oncology, Tadworth, United Kingdom; and D. Ross Camidge, University of Colorado Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451171PMC
June 2015

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Clin Cancer Res 2015 May;21(10):2227-35

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435823PMC
May 2015

Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.

Authors:
Alice T Shaw

Clin Adv Hematol Oncol 2015 May;13(5):282-4

Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2015

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2015 02;372(7):683-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1415359DOI Listing
February 2015

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-63

*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346098PMC
January 2015